If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Information on the effects of different pharmaceuticals on fertility is sparse. Human and animal models indicate that antidepressant use could have a negative effect on fertility through alteration of levels of the neurosteroid, allopregnanolone.
The objective of this study is to assess the effects of antidepressants on the natural fertility in women.
A secondary analysis of data from Time to Conceive, a prospective cohort study, was conducted. Women ages 30 to 44 years without a history of infertility, early in their attempts to conceive, were followed with standardized pregnancy testing until pregnancy was detected. Medication use was assessed at enrollment, daily for up to 4 months, and then monthly. For this analysis, discrete time regression models were created to calculate the association between antidepressant use and fecundability. Potential confounders—age, body mass index, caffeine, alcohol use, and education—were included in all models.
Ninety-two (9.6%) of 957 women reported antidepressant use while attempting to conceive. Women taking antidepressants were more likely to be non-Hispanic Caucasian (91% vs 75%, P < .01) and to consume alcoholic beverages (74% vs 61%, P < .01). Antidepressant use at enrollment had an adjusted fecundability ratio (FR) of 0.86 (95% confidence interval [CI], 0.63–1.20). However, time-varying analyses suggested that antidepressant use in a given cycle is associated with a reduced probability of conceiving in that cycle (adjusted FR, 0.75; 95% CI, 0.53–1.06). After adjusting for history of depression or restricting the analysis to women who reported a history of depression, the association between antidepressant use and decreased fecundability remained [adjusted FR, 0.66 (95% CI, 0.45–0.97) and (adjusted FR, 0.64; 95% CI, 0.43–0.94), respectively].
Our data suggest that antidepressants may reduce the probability of a woman with a history of depression to conceive naturally. Future studies are needed to differentiate the extent to which this association is due to the antidepressant itself versus the underlying depression.
a progesterone derivative considered a neurosteroid that is produced and is neuroactive in the brain. Allopregnanolone is a positive allosteric modulator of the gamma aminobutyric acid (GABAA) receptor. Its presence enhances the activity of GABA, which is the main inhibitory neurotransmitter in the central nervous system, including the hypothalamus.
Research on rodents suggests that an antidepressant-induced increase in allopregnanolone levels could lead to dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. Incubation of hypothalamic tissue with allopregnanolone suppresses GnRH release in a concentration-dependent manner. The effects are blocked with the addition of a GABA-antagonist, suggesting that allopregnanolone increases GABA activity, suppressing GnRH release.
and subsequently decreases rates of ovulation. This dysregulation in allopregnanolone could inhibit the pulsatile action of GnRH needed to sustain proper synchronization of ovulation, resulting in infertility.
The above evidence suggests that antidepressants may contribute to changes in the HPO axis through their GABAergic action. HPO axis dysfunction can manifest in numerous ways, including anovulation or luteal phase defects, which can negatively affect a woman’s ability to conceive. We hypothesized that antidepressant use would impair natural fertility, which we examined by analyzing the effect of antidepressants on fecundability, the probability of conceiving in a menstrual cycle.
Materials and Methods
This study is a secondary analysis of Time to Conceive (TTC), an ongoing prospective time-to-pregnancy cohort study approved by the institutional review board at the University of North Carolina. A detailed description of the TTC study has been published previously.
In brief, women were recruited to the study via community-based fliers, informational emails, internet, radio, television and print advertising, and community blogs. English-speaking women 30 to 44 years old, who had been attempting to conceive for less than 3 months, were eligible to participate. Women with a history of infertility, polycystic ovary syndrome, pelvic inflammatory disease, endometriosis, pelvic radiation, or a partner with a history of infertility were excluded. Our analysis includes women enrolled between April 2008 and July 2015. Information was collected via web-based questionnaires and daily diaries. At enrollment, women provided demographic information, medical and surgical history, obstetric, gynecologic, and menstrual history, information on behaviors, height and weight, and pregnancy history, as well as partner demographics. Women were asked if they had a history of anxiety or depression (yes/no). The question was not restricted to any specific type of depression or anxiety. The Cerner Multum drug database system was embedded to identify and record over-the-counter and prescription medication use. This comprehensive database included dosing information and drug names, both generic and brand names.
While attempting to conceive, women completed an online daily diary for 4 months or until pregnancy was detected. The daily diary collected information on vaginal bleeding, intercourse, pregnancy test results, and medication use. If the woman did not conceive in the first 4 months of enrollment, she completed an online questionnaire monthly thereafter, which also collected information on medication use. The women were followed for twelve months or until pregnancy was achieved. Pregnancy tests (sensitivity = 20 mIU hCG/mL) were provided with standardized instructions. For this analysis, a positive pregnancy test was our primary outcome of interest.
Antidepressants were categorized by class via mechanism of action. A comprehensive list of traditional antidepressants was constructed. Our list included selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, norepinephrine reuptake inhibitors, norepinephrine/dopamine reuptake inhibitors, tri and tetracyclic antidepressants (TCAs), monoamine oxidase inhibitors, and other antidepressants. Adjunct antidepressants and other psychotropic medications with antidepressant action were excluded.
Women were categorized by antidepressant use (yes/no). Antidepressant use was categorized by 1) use at enrollment, 2) use at any given time during the study, and 3) use in a given menstrual cycle. Bivariate analyses, with χ2 tests, were used to compare demographics and potential covariates (age, race, education level, pregnancy history, menstrual cycle regularity and length, frequency of intercourse, previous contraceptive use, body mass index [BMI], partner age, smoking status, alcohol use, and caffeine use) between the antidepressant users (at any given time in the study) and non-users.
Discrete-time survival models were constructed to assess the relationship between 1) antidepressant use at enrollment and fecundability and, as antidepressant use of an individual woman could vary over time, 2) antidepressant use in a given cycle and fecundability in that given cycle. All analyses were restricted to the first nine cycles of attempt, due to few women remaining after that time. All models accounted for both the right censoring and left truncation (due to women enrolling in cycles 1, 2, 3, or 4 of their pregnancy attempt) present in the data. In these models, a fecundability ratio (FR) less than 1.0 suggested reduced fecundability.
In all adjusted models we included both the covariates strongly associated with fecundability or antidepressants and those identified in multiple prior studies as related to fecundability. These covariates were age, Caucasian race (yes/no), BMI, education level, and alcohol use (yes/no). Maternal age was collapsed into three categories (30–34, 35–37, and 38–44 years of age), and BMI was categorized into 4 groups (≤18.4, 18.5–24.9, 25.0–29.9, and ≥30 kg/m2). Additional analyses adjusted for history of anxiety/depression as reported in the baseline questionnaire and restricted analysis to those women, who reported a history of anxiety/depression. In an attempt to explore the extent to which underlying anxiety/depression may play a role in the relationship between antidepressants and fertility, we analyzed the relationship between history of anxiety/depression, as reported in the baseline questionnaire and fecundability.
A total of 957 women and 3355 menstrual cycles were included in this analysis. Of the analysis cohort, 70% of women were 30 to 34 years old, 18% were 35 to 37 years old, and 12% were 38 to 44 years old. Participants tended to be Caucasian (76%), highly educated (72% with some graduate education or more), and normal weight (62%). Six hundred twenty-two (65%) of subjects conceived during their first 9 cycles of attempt. Analysis was restricted to the first nine cycles due to high levels of drop-out past this point.
Ninety-two (9.6%) women reported antidepressant use at some point during enrollment. Antidepressant use was reported by 7.6% of women in the first cycle of attempt, 9.0% in the second, 8.9% in the third, 8.2% in the sixth, and 11.0% in the eighth. The most frequently used antidepressants were SSRIs and all antidepressants, except one report of TCAs, were reuptake inhibitors. Women taking antidepressants were more likely to be non-Hispanic Caucasian (91% vs 75%, P < .01) and to consume alcoholic beverages (74% vs 61%, P < .01). There were no differences in other variables analyzed (Table 1). Menstrual cycle length and history of regular menstrual cycles did not differ at baseline by antidepressant use. Antidepressant users at enrollment reported on average 2.18 [standard deviation (SD) 1.25] acts of intercourse per week, which did not differ significantly from non-users at that time with 2.38 (SD 1.59) act per weeks (P = .27. Women reporting a history of depression had similar fecundability to those who did not (adjusted FR, 1.03; 95% CI, 0.82–1.24).
Table 1Baseline characteristics of women taking antidepressants
Antidepressant taken during study
No (%) n = 865
Yes (%) n = 92
38 and over
Less than college degree
Never been pregnant
Regular menstrual cycles
Body mass index (kg/m2)
Less than 18.5
30 and over
Partner age (years)
50 or more
Past year hormonal contraceptive use
Caffeinated beverage consumption
Average menstrual cycle length (days)
25 or fewer
36 or more
Casilla-Lennon et al. The effect of antidepressants on fertility. Am J Obstet Gynecol 2016.
Initial models suggested minimal to no effect of antidepressants on fecundability (Figure 1) when analyzing baseline antidepressant use; women who were taking antidepressants at enrollment had an adjusted FR of 0.86 (95% CI, 0.63–1.20). When analyzing cycles individually, time varying analyses suggested that antidepressant use in a given cycle was associated with a reduced probability of conceiving in that cycle (adjusted FR, 0.75; 95% CI, 0.53–1.06). After adjusting for a history of anxiety/depression as reported on the baseline questionnaire, the association between antidepressant use and fecundability remained [adjusted FR, 0.66 (95% CI, 0.45–0.97)]. When the analyses were restricted to women with a history of anxiety/depression, the association also remained (adjusted FR, 0.64; 95% CI, 0.43–0.94).
In this prospective cohort study we found that 9.6% of women took antidepressants while trying to conceive. Almost all antidepressants used in our study were reuptake inhibitors, sharing a similar mechanism of action. Women in our study who took antidepressants tended to be non-Hispanic Caucasian and more likely to consume alcoholic beverages. History of depression or anxiety was not associated with fecundability. Antidepressant use within a given menstrual cycle was associated with a lower probability of conceiving among women who reported a history of anxiety or depression.
Antidepressant use in our cohort was similar to that in previous studies. A cross-sectional study of 12,637 Americans found antidepressant use in women ages 18 to 39 years to be 9.2%.
In our study antidepressant users did not differ from non-users by race or age. The age distribution did not significantly differ by antidepressant use. Regarding race distribution, 79% of antidepressant users were Non-Hispanic Caucasian, whereas 76% of non-users were non-Hispanic Caucasian. Our inability to detect previously observed associations may be due to the relatively narrow age range and underrepresentation of minorities in this study.
We did not find any differences in the reported regularity or length of menstrual cycles between women using and not using antidepressants. If menstrual cycle characteristics had been different between groups, this may have suggested HPO axis dysfunction. However, menstrual cycles tend to be highly variable,
and a lack of these findings does not exclude the possibility of HPO axis dysregulation leading to anovulation or luteal phase defects.
Our study found lower fecundability in cycles in which a woman took an antidepressant. This finding was statistically significant after adjusting for history of anxiety or depression or restricting the analysis to those that reported a history of anxiety or depression. To our knowledge, this is the first prospective study to look at the effect of antidepressants on fertility. In a case control study, Grodstein et al
performed a retrospective study to analyze the effect of SSRIs on the success of IVF treatments, reporting that the group of women using SSRIs had a lower pregnancy rate than non-users (40% vs 51%). Their findings were limited by a small sample size and were not statistically significant.
The observed association between antidepressants and fecundability could be due to the antidepressants itself or the underlying fertility. This study was not designed to look at the relationship between depression and fecundability. There was a single question on the enrollment questionnaire that queried about history of underlying depression or anxiety. This simple measure was not associated with fecundability. However, we are unable to determine the extent to which antidepressants users or non-users suffered from depression or residual depressive symptoms. Therefore, this study is unable to truly differentiate the effect of the underlying depression from the antidepressant. Future studies could use validated questionnaires to assess anxiety and depression symptoms.
The true relationship between depression and fertility is unknown. Odegard found in a study of 30,438 married or previously married women in Norway hospitalized for psychiatric disorders, that women with affective psychoses had a similar number of observed children as expected for the general population.
found, in a prospective cohort of women going through menopause, that women with a history of depression reported fewer live births. Neither of these studies account for desires to conceive. In a prospective time-to-pregnancy study, Lynch et al
used the Hospital Anxiety and Depression Scale to assess the association between depression and fecundability. They did not find an association between depression scores and fecundability. However, depression scores for their cohort were within the normal range; thus they were not able to assess the impact of depressive disorders.
examined the relationship between antidepressant use and miscarriage using a pharmacy database. The authors found an increased risk of miscarriage in those women taking antidepressants during the first trimester (1.27 HR; 95% CI, 1.22–1.33) compared with women who did not. However, they found a similarly increased risk of miscarriage in those women who stopped the antidepressant prior to conceiving (1.24 HR; 95% CI, 1.18–1.30). This would suggest a potential for confounding by indication with this class of medication. To try to account for the possibility of confounding by indication, we restricted our analysis to women who reported a history of anxiety/depression. However, we did not account for current disease or severity of disease. Future studies may need to collect more information to allow the use of propensity scores (to predict probability of using antidepressants) in analyses.
Our study is not without limitations. By design it includes older reproductive-aged women. While this increases the prevalence of antidepressant use, it may decrease generalizability. Although we identified numerous variables known to affect both depression and fertility, the nature of an observational study precludes us from adjusting for all possible confounders. The outcome we used was an epidemiological measure of fecundability, not incidence of infertility, and the outcome was pregnancy, not live birth. One would presume, however, that decreased fecundability would result in increased rates of infertility. Because our study was not originally designed to assess depression, we relied on a self-report of a history of depression/anxiety. As discussed above, this study cannot differentiate between active or past depression nor between anxiety and depression.
Our study design was the most important strength of our study. A prospective cohort provides the strongest evidence when assessing pharmaceuticals on women attempting to conceive, as randomized controlled trials are not done in this context.
Cross-sectional studies are limited by their inability to determine temporal causality. The online self-reported daily diaries allowed for accuracy, as well as privacy, compared with face-to-face interviews, which may be especially important when assessing sensitive information.
To further improve accuracy by avoiding misclassification and monitoring adherence of antidepressants, the Center Multum drug database was used.
In conclusion, antidepressants are among the most widely used medications in reproductive-aged women in the United States. Our study suggests that antidepressant use in women with a history of anxiety or depression diminishes natural fertility. While this is concerning, it is possible that the indication for the antidepressant is the causal factor. Thus, this study alone cannot be used as justification for women to stop their antidepressants when attempting to conceive.
Major depressive disorder treatment guidelines in America and Europe.